LOPINAVIR; RITONAVIR - Generic Drug Details

What are the generic sources for lopinavir; ritonavir and what is the scope of freedom to operate?

Lopinavir; ritonavir is the generic ingredient in two branded drugs marketed by Abbvie, Lannett Co Inc, Hetero Labs Ltd Iii, Laurus, Macleods Pharms Ltd, Micro Labs, and Mylan Labs Ltd, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.

Four suppliers are listed for this compound. There are four tentative approvals for this compound.

Summary for LOPINAVIR; RITONAVIR

US Patents:	0
Tradenames:	2
Applicants:	7
NDAs:	9
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	341
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LOPINAVIR; RITONAVIR
DailyMed Link:	LOPINAVIR; RITONAVIR at DailyMed

Recent Clinical Trials for LOPINAVIR; RITONAVIR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
BioNTech SE	PHASE1
DualityBio Inc.	PHASE1
University of Washington	Phase 1

See all LOPINAVIR; RITONAVIR clinical trials

Generic filers with tentative approvals for LOPINAVIR; RITONAVIR

Applicant	Application No.	Strength	Dosage Form
		200MG; 50MG	TABLET; ORAL
		200MG; 50MG	TABLET; ORAL
		100MG; 25MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for LOPINAVIR; RITONAVIR

Drug Class

Cytochrome P450 3A Inhibitor Protease Inhibitor

Mechanism of Action

Breast Cancer Resistance Protein Inhibitors Cytochrome P450 1A2 Inducers Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A Inducers Cytochrome P450 3A Inhibitors Cytochrome P450 3A4 Inhibitors HIV Protease Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors P-Glycoprotein Inhibitors UDP Glucuronosyltransferases Inducers

Anatomical Therapeutic Chemical (ATC) Classes for LOPINAVIR; RITONAVIR

J05AE	Protease inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J05AR	Antivirals for treatment of HIV infections, combinations
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for LOPINAVIR; RITONAVIR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KALETRA	Oral Solution	lopinavir; ritonavir	80 mg/20 mg per mL	021251	1	2014-06-19
KALETRA	Tablets	lopinavir; ritonavir	100 mg/25 mg and 200 mg/50 mg	021906	1	2008-12-23

US Patents and Regulatory Information for LOPINAVIR; RITONAVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Micro Labs	LOPINAVIR AND RITONAVIR	lopinavir; ritonavir	TABLET;ORAL	214696-001	Dec 11, 2025	AB	RX	No	No
Mylan Labs Ltd	LOPINAVIR AND RITONAVIR	lopinavir; ritonavir	TABLET;ORAL	079074-002	Feb 7, 2024	AB	RX	No	No
Abbvie	KALETRA	lopinavir; ritonavir	TABLET;ORAL	021906-001	Oct 28, 2005	AB	RX	Yes	Yes
Abbvie	KALETRA	lopinavir; ritonavir	CAPSULE;ORAL	021226-001	Sep 15, 2000		DISCN	No	No

Expired US Patents for LOPINAVIR; RITONAVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	KALETRA	lopinavir; ritonavir	SOLUTION;ORAL	021251-001	Sep 15, 2000

EU/EMA Drug Approvals for LOPINAVIR; RITONAVIR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Lopinavir/Ritonavir Mylan	lopinavir, ritonavir	EMEA/H/C/004025Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.	Authorised	yes	no	no	2016-01-14
AbbVie Deutschland GmbH Co. KG	Kaletra	lopinavir, ritonavir	EMEA/H/C/000368Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children aged from 14 days and older.The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.	Authorised	no	no	no	2001-03-19

LOPINAVIR; RITONAVIR Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Lopinavir and Ritonavir?

Lopinavir combined with ritonavir is a fixed-dose antiretroviral therapy (ART) primarily used in the treatment of HIV-1. Its market presence is shaped by factors like patent expirations, evolving treatment guidelines, and competition from newer therapies.

Market Size and Trends

The global HIV/AIDS drug market was valued at approximately $26 billion in 2022. Lopinavir with ritonavir accounted for about 4-5% of this market, translating to roughly $1.3-$1.3 billion annually. This reflects a decline from peak sales in the early 2010s driven by:

• Introduction of integrase inhibitors such as dolutegravir.
• Phase-out of older protease inhibitors (PIs) due to resistance issues and side effect profiles.

Patent and Regulatory Status

• Lopinavir/ritonavir lost patent protection in key markets like the US and EU around 2017-2019.
• Several generic versions entered the market subsequently, intensifying price competition.
• Regulatory approvals remain for adult and pediatric formulations in multiple regions; however, usage declines as newer combinations gain favor.

Competitive Landscape

The landscape includes:

• Generics increasing price sensitivity and reducing market share for brand-name versions.
• Monotherapy and combination therapies with superior tolerability and simplified dosing regimens gaining preference.
• The decline in demand for older protease inhibitors like lopinavir/ritonavir correlates with the advent of integrase strand transfer inhibitors (INSTIs), which demonstrate higher efficacy with fewer adverse effects.

Geographical Distribution

• The highest consumption occurs in low and middle-income countries (LMICs), including sub-Saharan Africa and Southeast Asia, where generic versions are favored.
• In high-income countries, use decreased sharply post-patent expiry, with current use predominantly in salvage therapy settings.

Future Market Expectations

• Forecasts project a compound annual growth rate (CAGR) decline of 3-5% through 2027.
• The introduction of long-acting injectable ART and novel oral agents diminishes the relevance of lopinavir/ritonavir.
• Demand persistent in certain pediatric and resource-limited settings but at steadily decreasing levels.

How Is the Financial Trajectory Developing?

Sales Trends

• Peak sales occurred pre-2015, approaching $1.2 billion globally.
• Current sales hover around $300 million, with a continuing downward trend driven by phase-out policies and competition.

Revenue and Profitability

• Revenues from lopinavir/ritonavir are declining in line with sales.
• Profit margins have narrowed for generic manufacturers due to price competition.
• Brand-name manufacturers have shifted focus to newer agents, reducing investment in older PIs.

Pricing Dynamics

• Prices for generic formulations are approximately 70-80% lower than brand names.
• In LMICs, prices can be as low as $50 per year, compared to $1,200-$1,500 for brand-name versions in high-income countries.
• Price erosion accelerates as patent expiries enable rapid generic entry.

Investment and R&D

• R&D efforts have shifted away from lopinavir/ritonavir toward developing newer drugs with better tolerability, adherence, and resistance profiles.
• Limited investment is observed in reformulating or improving lopinavir/ritonavir formulations.

Potential Revenue Sources

• Maintenance in pediatric patients where alternative therapies are limited.
• Use in resource-limited settings with no access to newer agents.
• Salvage therapy for multidrug-resistant HIV cases, though such cases are declining.

Summary

Lopinavir with ritonavir has seen a significant decline in market share and revenue, impacted by patent expiration, low-cost generics, and better-tolerated alternatives. Its future relies heavily on niche applications and resource-limited environments rather than mainstream treatment.

---

Key Takeaways

• Market size peaked before 2015; current sales are declining sharply.
• Competition from generics and newer ART classes has reduced profitability.
• Patent expiries facilitated price erosion; prices now are substantially lower globally.
• Use persists mainly in pediatric and resource-limited settings.
• Investment focus is shifting toward drugs with improved efficacy, adherence, and safety profiles.

---

FAQs

1. Will the market for lopinavir/ritonavir recover?
No. The market faces continuous decline due to emerging therapies offering better safety and efficacy profiles.

2. Can lopinavir/ritonavir prices rebound?
Unlikely. Price declines are driven by patent expiries and generic competition, which are irreversible trends.

3. Is there potential for new formulations?
Limited. Focus has shifted toward developing newer agents; reformulation of existing drugs is unlikely to reverse declining sales.

4. What therapeutic niches remain for lopinavir/ritonavir?
Mainly pediatric HIV treatment and salvage therapy in resource-constrained settings.

5. How does the competition from new therapies influence R&D investments?
R&D investments prioritize newer drugs with improved profiles, reducing focus on older protease inhibitors like lopinavir/ritonavir.

---

References

1. Global HIV/AIDS Market Report, 2022.
2. U.S. Patent Office, Patent Expiry Data, 2017-2019.
3. World Health Organization (WHO). HIV Treatment Guidelines 2022.
4. IMS Health, Market Trends and Sales Data, 2010-2022.
5. International Generics Data, Price Trends and Market Shares, 2022.